Trygve Holmøy

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 17

Top Topics

Rheumatoid Arthritis Patients

Disease Activity

Listeria Monocytogenes

Multiple Sclerosis

Top Venues

Amyotrophic lateral sclerosis & frontotemporal degeneration

Case reports in genetics

This page only lists publications with an associated author ORCID identifier.

Publications

Anders Myhre Vaage, Jūratė Šaltytė Benth, Haakon E Meyer, Trygve Holmøy, Ola Nakken
Premorbid lipid levels and long-term risk of ALS-a population-based cohort study. Amyotrophic lateral sclerosis & frontotemporal degeneration 25 (3-4) (2023)
Anders Myhre Vaage, Jūratė Šaltytė Benth, Haakon E Meyer, Trygve Holmøy, Ola Nakken
Premorbid lipid levels and long-term risk of ALS-a population-based cohort study. Amyotrophic lateral sclerosis & frontotemporal degeneration (2023)
Anders Myhre Vaage, Jūratė Šaltytė Benth, Haakon E Meyer, Trygve Holmøy, Ola Nakken
Premorbid lipid levels and long-term risk of ALS-a population-based cohort study. Amyotrophic lateral sclerosis & frontotemporal degeneration 25 (3-4) (2023)
Helle Høyer, Ola Nakken, Trygve Holmøy
A Novel SPAST Variant Associated with Isolated Spastic Paraplegia. Case reports in genetics 2023 (2023)
Helle Høyer, Ola Nakken, Trygve Holmøy
A Novel SPAST Variant Associated with Isolated Spastic Paraplegia. Case reports in genetics 2023 (2023)
Rune Alexander Høglund, Haakon E Meyer, Hein Stigum, Øivind Fredvik Torkildsen, Nina Grytten, Trygve Holmøy, Ola Nakken
Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study. Neurology 97 (23) (2021)
Trygve Holmøy, Rune Alexander Høglund, Zsolt Illes, Kjell-Morten Myhr, Øivind Torkildsen
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of neurology 268 (12) (2020)
Joost Smolders, Øivind Torkildsen, William Camu, Trygve Holmøy
An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS drugs 33 (12) (2020)
Trygve Holmøy, Børre Fevang, David Benee Olsen, Olav Spigset, Lars Bø
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC research notes 12 (1) (2019)
Ola Nakken, Haakon E Meyer, Hein Stigum, Trygve Holmøy
High BMI is associated with low ALS risk: A population-based study. Neurology 93 (5) (2019)
Trygve Holmøy, Øivind Torkildsen, Svetozar Zarnovicky
Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab. Case reports in neurological medicine 2018 (2018)
Alina Tomescu-Baciu, Frode Vartdal, Trygve Holmøy, Christian A Vedeler, Andreas Lossius
G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis. Annals of clinical and translational neurology 5 (10) (2018)
Trygve Holmøy, Egil Røsjø, Henrik Zetterberg, Kaj Blennow, Jonas Christoffer Lindstrøm, Linn Hofsøy Steffensen, Margitta T Kampman
Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta neurologica Scandinavica 139 (2) (2018)
Trygve Holmøy, Jonas Christoffer Lindstrøm, Erik Fink Eriksen, Linn Hofsøy Steffensen, Margitta T Kampman
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC neurology 17 (1) (2017)
Trygve Holmøy, Hedda von der Lippe, Truls Michael Leegaard
Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies. BMC neurology 17 (1) (2017)
Ola Nakken, Jonas Christoffer Lindstrøm, Ole-Bjørn Tysnes, Trygve Holmøy
Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic lateral sclerosis & frontotemporal degeneration 19 (3-4) (2017)
Trygve Holmøy, Antonie G Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø, Emilia Kerty
Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report. BMC neurology 16 (1) (2016)